FDA OKs First Gene Therapy for Hemophilia B
The FDA on Tuesday approved the first gene therapy for treating hemophilia B, a genetic bleeding disorder resulting from missing or insufficient levels of factor IX. Etranacogene dezaparvovec (Hemgenix) is indicated for adults with the condition who currently use factor IX prophylaxis therapy for blood clotting, those who have or have had life-threatening hemorrhage, or […]
Gene Therapy Makes Inroads Against a Form of Hemophilia
Latest Chronic Pain News FRIDAY, July 22, 2022 (HealthDay News) People with hemophilia B could find their bleeding risk dramatically reduced with just one injection of an experimental gene therapy, a new study reports. Hemophilia B is a rare and inherited genetic disorder in which people have low levels of the factor IX (FIX) protein, […]